0001104659-20-032487.txt : 20200312
0001104659-20-032487.hdr.sgml : 20200312
20200312161201
ACCESSION NUMBER: 0001104659-20-032487
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200310
FILED AS OF DATE: 20200312
DATE AS OF CHANGE: 20200312
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Myles Edward H
CENTRAL INDEX KEY: 0001358219
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-10865
FILM NUMBER: 20708900
MAIL ADDRESS:
STREET 1: C/O AMAG PHARMACEUTICALS, INC.
STREET 2: 1100 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AMAG PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0000792977
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 042742593
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1100 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 6174983300
MAIL ADDRESS:
STREET 1: 1100 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
FORMER COMPANY:
FORMER CONFORMED NAME: AMAG PHARMACEUTICALS INC.
DATE OF NAME CHANGE: 20070724
FORMER COMPANY:
FORMER CONFORMED NAME: ADVANCED MAGNETICS INC
DATE OF NAME CHANGE: 19920703
4
1
a4.xml
4
X0306
4
2020-03-10
0
0000792977
AMAG PHARMACEUTICALS, INC.
AMAG
0001358219
Myles Edward H
C/O AMAG PHARMACEUTICALS, INC.,
1100 WINTER STREET
WALTHAM
MA
02451
0
1
0
0
COO & CFO
Common Stock
2020-03-10
4
A
0
30000
A
98659
D
Stock Option (Right to Buy)
7.27
2020-03-10
4
A
0
45000
A
2030-03-10
Common Stock
45000
45000
D
Each restricted stock unit ("RSU") represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer").
These shares of Common Stock are issuable pursuant to a grant of RSUs pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan") that will vest in three equal annual installments with the first installment vesting on March 10, 2021.
Not applicable.
Grant of stock option pursuant to the Plan. This option will vest and become exercisable over four years after the grant date as follows: (i) 25% on the first anniversary of the grant date and (ii) the balance vesting in equal quarterly installments over the next three years thereafter.
/s/ Joseph Vittiglio, attorney-in-fact
2020-03-12